Biotrin Announces Agreement with BD Biosciences
Complete the form below to unlock access to ALL audio articles.
Biotrin has announced an agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company), for the distribution of Biotrin's biomarker range of products for the detection of early organ damage.
Under the terms of the distribution agreement, BD Biosciences has been appointed as world-wide distributor of the Biotrin Biomarkers product range to pharmaceutical companies, contract research organisations, universities and research centres.
"We believe this agreement will enable us to capitalize on the growing demand for our expanding biomarker product line and help achieve our goal of making Biotrin Biomarkers the number one choice for the detection of early organ damage," said Dr. Cormac G. Kilty, CEO of Biotrin.
"With the sales and marketing teams from Biotrin and BD Biosciences working together, we will expand the reach of this product line throughout the world."
Biotrin identifies and selects biomarkers of interest using proprietary HISTOMICS® technology.
Biotrin Biomarkers are designed to provide specific and quantitative information allowing researchers to determine the exact location and amount of damage an organ has undergone and to monitor the progression of damage, either as a result of disease or the administration of toxic compounds.
Under the agreement, BD Biosciences will sell the Biotrin Biomarkers product range throughout the world.
